Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases

D. A. Katzka, E. V. Loftus, M. Camilleri

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Novel treatments for gastrointestinal (GI) diseases are based on molecular targets. Novel pharmacologic and biological agents with greater selectivity and specificity are being developed for a variety of epithelial diseases, including eosinophilic esophagitis (EoE), gastroesophageal reflux disease (GERD), celiac disease, short bowel syndrome (SBS), and inflammatory bowel diseases (IBDs; Crohn's disease and ulcerative colitis). Motility and secretory agents are being developed for gastroparesis, irritable bowel syndrome (IBS), functional constipation, and diarrhea. Here we focus on data from clinical trials involving validated pharmacodynamic or patient response outcomes.

Original languageEnglish (US)
Pages (from-to)306-320
Number of pages15
JournalClinical pharmacology and therapeutics
Issue number3
StatePublished - Sep 1 2012

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases'. Together they form a unique fingerprint.

Cite this